{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T21:01:45Z","timestamp":1771707705855,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and objective<\/jats:title>\n                <jats:p>Tuberous sclerosis (TS) is a condition whose manifestations in childhood have been extensively described, but whose presentation in adults is less well known. This study describes the clinical and genetic characteristics, therapeutic management and quality of life of a cohort of adult patients with TS. A comparative study of the characteristics of patients diagnosed in childhood and adulthood is also carried out.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material and methods<\/jats:title>\n                <jats:p>This observational, retrospective, cross-sectional study included a large cohort of adult patients (\u2265\u200916\u00a0years old) followed for 5\u00a0years in a specific rare diseases unit.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty-seven patients with a diagnosis of tuberous sclerosis were included, more than 50% of whom were diagnosed as adults. The mean age of the patients was 42\u00a0years (20\u201386). The central nervous system was the main area affected (97%), followed by the skin (80.7%) and kidneys (73%). The most frequent genetic alteration was a mutation in the <jats:italic>TSC2<\/jats:italic> gene (47.7%). Among patients diagnosed in adulthood, there was less neurological involvement, with less frequency of epileptic seizures (30.8% vs 60.79% of patients diagnosed in childhood) and astrocytomas (3.8% vs 53.6%), less intellectual disability (11.5% vs 71.4%) and less expressiveness of the condition. 42% of patients were treated with mTOR pathway inhibitors, and presence of an angiomyolipoma was the main indication. In a quality-of-life analysis, the means of the summary indices were below the scores of the average Spanish population: (47.42 (SD\u2009\u00b1\u20099.82) on the physical health scale, 45.61 (SD\u2009\u00b1\u20097.99) on the mental health scale) versus 50 (SD\u2009\u00b1\u200910) for the general population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Up to 50% of adult patients with TS were diagnosed in adulthood, and the condition is less severe with less frequent epileptic seizures and intellectual disability. 42% require treatment with mTOR inhibitors, in most cases due to the presence of AMLs. The quality of life of adult patients with TS is diminished compared to the general population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01878-2","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T08:04:21Z","timestamp":1622448261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical, genetic and quality-of-life study of a cohort of adult patients with tuberous sclerosis"],"prefix":"10.1186","volume":"16","author":[{"given":"Elena Cristina","family":"De Sautu De Borb\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Guerra Vales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Lumbreras Bermejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Guerrero Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Buj Padilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Gonz\u00e1lez de la Aleja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Morales Conejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"issue":"10","key":"1878_CR1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/sj.ejhg.5201625","volume":"14","author":"JR Yates","year":"2006","unstructured":"Yates JR. Tuberous sclerosis. Eur J Hum Genet. 2006;14(10):1065\u201373. https:\/\/doi.org\/10.1038\/sj.ejhg.5201625.","journal-title":"Eur J Hum Genet"},{"issue":"9114","key":"1878_CR2","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/S0140-6736(05)78872-3","volume":"351","author":"FJ O'Callaghan","year":"1998","unstructured":"O\u2019Callaghan FJ, Shiell AW, Osborne JP, Martyn CN. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet. 1998;351(9114):1490. https:\/\/doi.org\/10.1016\/S0140-6736(05)78872-3.","journal-title":"Lancet"},{"key":"1878_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1749-6632.1991.tb37754.x","volume":"615","author":"JP Osborne","year":"1991","unstructured":"Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:125\u20137. https:\/\/doi.org\/10.1111\/j.1749-6632.1991.tb37754.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"1878_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13023-018-0870-y","volume":"13","author":"D Ebrahimi-Fakhari","year":"2018","unstructured":"Ebrahimi-Fakhari D, Mann LL, Poryo M, et al. Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study. Orphanet J Rare Dis. 2018;13(1):117. https:\/\/doi.org\/10.1186\/s13023-018-0870-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1878_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13023-019-1090-9","volume":"14","author":"D Ebrahimi-Fakhari","year":"2019","unstructured":"Ebrahimi-Fakhari D, Mann LL, Poryo M, et al. Correction to: Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study. Orphanet J Rare Dis. 2019;14(1):106. https:\/\/doi.org\/10.1186\/s13023-019-1090-9.","journal-title":"Orphanet J Rare Dis"},{"issue":"13","key":"1878_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"PB Crino","year":"2006","unstructured":"Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345\u201356. https:\/\/doi.org\/10.1056\/NEJMra055323.","journal-title":"N Engl J Med"},{"key":"1878_CR7","doi-asserted-by":"publisher","unstructured":"Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49(4):243\u2013254. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2013.08.001","DOI":"10.1016\/j.pediatrneurol.2013.08.001"},{"key":"1878_CR8","doi-asserted-by":"publisher","unstructured":"Krueger DA, Northrup H; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49(4):255\u2013265. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2013.08.002","DOI":"10.1016\/j.pediatrneurol.2013.08.002"},{"issue":"9861","key":"1878_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(12)61134-9.","journal-title":"Lancet"},{"key":"1878_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-016-0658-4","volume":"16","author":"A Fogarasi","year":"2016","unstructured":"Fogarasi A, De Waele L, Bartalini G, et al. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. BMC Neurol. 2016;16:126. https:\/\/doi.org\/10.1186\/s12883-016-0658-4.","journal-title":"BMC Neurol"},{"key":"1878_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26347","author":"J Trelinska","year":"2017","unstructured":"Trelinska J, Dachowska I, Baranska D, et al. Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study). Pediatr Blood Cancer. 2017. https:\/\/doi.org\/10.1002\/pbc.26347.","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"1878_CR12","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1212\/WNL.0000000000003400","volume":"87","author":"DA Krueger","year":"2016","unstructured":"Krueger DA, Wilfong AA, Mays M, et al. Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology. 2016;87(23):2408\u201315. https:\/\/doi.org\/10.1212\/WNL.0000000000003400.","journal-title":"Neurology"},{"issue":"10056","key":"1878_CR13","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(16)31419-2.","journal-title":"Lancet"},{"issue":"9869","key":"1878_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(12)61767-X.","journal-title":"Lancet"},{"issue":"8","key":"1878_CR15","doi-asserted-by":"publisher","first-page":"e0180939","DOI":"10.1371\/journal.pone.0180939","volume":"12","author":"JJ Bissler","year":"2017","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study. PLoS ONE. 2017;12(8):e0180939. https:\/\/doi.org\/10.1371\/journal.pone.0180939.","journal-title":"PLoS ONE"},{"key":"1878_CR16","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.3389\/fneur.2019.01144","volume":"10","author":"R Marques","year":"2019","unstructured":"Marques R, Belousova E, Benedik MP, et al. Treatment patterns and use of resources in patients with tuberous sclerosis complex: insights from the TOSCA registry. Front Neurol. 2019;10:1144. https:\/\/doi.org\/10.3389\/fneur.2019.01144.","journal-title":"Front Neurol"},{"issue":"1","key":"1878_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13023-019-1072-y","volume":"14","author":"S Auvin","year":"2019","unstructured":"Auvin S, Bissler JJ, Cottin V, et al. A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report. Orphanet J Rare Dis. 2019;14(1):91. https:\/\/doi.org\/10.1186\/s13023-019-1072-y.","journal-title":"Orphanet J Rare Dis"},{"key":"1878_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2019-106607","author":"P Pfirmann","year":"2020","unstructured":"Pfirmann P, Aupy J, Jambon E, et al. Description of a multidisciplinary model of care in a French cohort of adult patients with tuberous sclerosis complex. J Med Genet. 2020. https:\/\/doi.org\/10.1136\/jmedgenet-2019-106607.","journal-title":"J Med Genet"},{"issue":"8","key":"1878_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.medcli.2018.08.004","volume":"153","author":"RE BautistaAlonso","year":"2019","unstructured":"BautistaAlonso RE, ArtajonaRodrigo E, PovarEcheverr\u00eda M. Tuberous sclerosis complex in a third level hospital: need for integral management. Esclerosis tuberosa en un hospital de tercer nivel: necesidad de un abordaje integral. Med Clin Barc. 2019;153(8):338\u20139. https:\/\/doi.org\/10.1016\/j.medcli.2018.08.004.","journal-title":"Med Clin Barc."},{"issue":"3","key":"1878_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ajmg.c.31653","volume":"178","author":"A Peron","year":"2018","unstructured":"Peron A, Canevini MP, Ghelma F, Di Marco F, Vignoli A. Healthcare transition from childhood to adulthood in Tuberous Sclerosis Complex. Am J Med Genet C Semin Med Genet. 2018;178(3):355\u201364. https:\/\/doi.org\/10.1002\/ajmg.c.31653.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"1878_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12881-015-0155-4","volume":"16","author":"M Nellist","year":"2015","unstructured":"Nellist M, Brouwer RW, Kockx CE, et al. Targeted next generation sequencing reveals previously unidentified TSC1 and TSC2 mutations. BMC Med Genet. 2015;16:10. https:\/\/doi.org\/10.1186\/s12881-015-0155-4.","journal-title":"BMC Med Genet"},{"issue":"3","key":"1878_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ejpn.2018.01.026","volume":"22","author":"A Papadopoulou","year":"2018","unstructured":"Papadopoulou A, Dinopoulos A, Koutsodontis G, et al. Screening for TSC1 and TSC2 mutations using NGS in Greek children with tuberous sclerosis syndrome. Eur J Paediatr Neurol. 2018;22(3):419\u201326. https:\/\/doi.org\/10.1016\/j.ejpn.2018.01.026.","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"1878_CR23","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ejpn.2019.09.006","volume":"23","author":"S Amin","year":"2019","unstructured":"Amin S, Mallick AA, Lux A, O\u2019Callaghan F. Quality of life in patients with Tuberous Sclerosis Complex (TSC). Eur J Paediatr Neurol. 2019;23(6):801\u20137. https:\/\/doi.org\/10.1016\/j.ejpn.2019.09.006.","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"1878_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.pediatrneurol.2014.11.013","volume":"52","author":"AM Rentz","year":"2015","unstructured":"Rentz AM, Skalicky AM, Liu Z, et al. Tuberous sclerosis complex: a survey of health care resource use and health burden. Pediatr Neurol. 2015;52(4):435\u201341. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2014.11.013.","journal-title":"Pediatr Neurol"},{"issue":"10","key":"1878_CR25","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1136\/archdischild-2018-316394","volume":"104","author":"CY Fong","year":"2019","unstructured":"Fong CY, Ng K, Kong AN, et al. Quality of life of children with tuberous sclerosis complex. Arch Dis Child. 2019;104(10):972\u20138. https:\/\/doi.org\/10.1136\/archdischild-2018-316394.","journal-title":"Arch Dis Child"},{"issue":"8943","key":"1878_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/s0140-6736(95)90213-9","volume":"345","author":"S Verhoef","year":"1995","unstructured":"Verhoef S, Vrtel R, van Essen T, et al. Somatic mosaicism and clinical variation in tuberous sclerosis complex. Lancet. 1995;345(8943):202. https:\/\/doi.org\/10.1016\/s0140-6736(95)90213-9.","journal-title":"Lancet"},{"issue":"1","key":"1878_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1086\/316951","volume":"68","author":"SL Dabora","year":"2001","unstructured":"Dabora SL, Jozwiak S, Franz DN, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68(1):64\u201380. https:\/\/doi.org\/10.1086\/316951.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1878_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13023-016-0553-5","volume":"12","author":"JC Kingswood","year":"2017","unstructured":"Kingswood JC, d\u2019Aug\u00e8res GB, Belousova E, et al. TuberOus SClerosis registry to increase disease awareness (TOSCA)-baseline data on 2093 patients. Orphanet J Rare Dis. 2017;12(1):2. https:\/\/doi.org\/10.1186\/s13023-016-0553-5.","journal-title":"Orphanet J Rare Dis"},{"key":"1878_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13023-014-0182-9","volume":"9","author":"JC Kingswood","year":"2014","unstructured":"Kingswood JC, Bruzzi P, Curatolo P, et al. TOSCA-first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. Orphanet J Rare Dis. 2014;9:182. https:\/\/doi.org\/10.1186\/s13023-014-0182-9.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"1878_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ajmg.c.31647","volume":"178","author":"DS Lu","year":"2018","unstructured":"Lu DS, Karas PJ, Krueger DA, Weiner HL. Central nervous system manifestations of tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):291\u20138. https:\/\/doi.org\/10.1002\/ajmg.c.31647.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"4","key":"1878_CR31","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00401-019-02003-1","volume":"139","author":"JA Cotter","year":"2020","unstructured":"Cotter JA. An update on the central nervous system manifestations of tuberous sclerosis complex. Acta Neuropathol. 2020;139(4):613\u201324. https:\/\/doi.org\/10.1007\/s00401-019-02003-1.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"1878_CR32","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","volume":"14","author":"P Curatolo","year":"2015","unstructured":"Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015;14(7):733\u201345. https:\/\/doi.org\/10.1016\/S1474-4422(15)00069-1.","journal-title":"Lancet Neurol"},{"key":"1878_CR33","doi-asserted-by":"publisher","unstructured":"Hinton RB, Prakash A, Romp RL, Krueger DA, Knilans TK. International Tuberous Sclerosis Consensus Group. Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group. J Am Heart Assoc. 2014;3(6):e001493. https:\/\/doi.org\/10.1161\/JAHA.114.001493","DOI":"10.1161\/JAHA.114.001493"},{"issue":"19","key":"1878_CR34","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1157\/13121076","volume":"130","author":"G Vilagut","year":"2008","unstructured":"Vilagut G, Valderas JM, Ferrer M, Garin O, L\u00f3pez-Garc\u00eda E, Alonso J. Interpretaci\u00f3n de los cuestionarios de salud SF-36 y SF-12 en Espa\u00f1a: componentes f\u00edsico y mental [Interpretation of SF-36 and SF-12 questionnaires in Spain: physical and mental components]. Med Clin (Barc). 2008;130(19):726\u201335. https:\/\/doi.org\/10.1157\/13121076.","journal-title":"Med Clin (Barc)"},{"issue":"11","key":"1878_CR35","first-page":"410","volume":"111","author":"J Alonso","year":"1998","unstructured":"Alonso J, Regidor E, Barrio G, Prieto L, Rodr\u00edguez C, de la Fuente L. Valores poblacionales de referencia de la versi\u00f3n espa\u00f1ola del Cuestionario de Salud SF-36 [Population reference values of the Spanish version of the Health Questionnaire SF-36]. Med Clin (Barc). 1998;111(11):410\u20136.","journal-title":"Med Clin (Barc)"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01878-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01878-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01878-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T08:09:36Z","timestamp":1622448576000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01878-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1878"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01878-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]},"assertion":[{"value":"25 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was presented and accepted by the Ethics Committee for Research at the University Hospital 12 October, in accordance with current legislation, and has been conducted in compliance with the principles set out in the Helsinki Declaration and the standards of good clinical practice. Consent was delivered at one of the scheduled visits.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}